AR/VR Medical Devices: Regulatory Pathway, FDA-Cleared Devices, and Classification Guide (2026)

AR/VR in Healthcare Is No Longer Experimental

The FDA's public list of medical devices incorporating augmented reality (AR) and virtual reality (VR) technologies now contains 104 entries — a 167% increase from the 39 entries published in December 2022 (FDA; Exponent analysis, February 2026). These devices span surgical navigation, therapeutic interventions for pain and behavioral health, diagnostic imaging, ophthalmic treatment, and surgical training. The majority were cleared through the 510(k) pathway, with two De Novo authorizations.

This is not a niche. AR/VR medical devices are being cleared at an accelerating pace, with companies like Augmedics (xvision Spine System), Medivis (SurgicalAR), Brainlab (Mixed Reality Viewer), AppliedVR (RelieVRx), and Apple (Digital Prism Correction) all receiving FDA clearance in 2025 alone. The regulatory framework for these devices is maturing, but it presents unique challenges that differ from traditional medical devices.

This guide covers how AR/VR medical devices are classified, which regulatory pathways apply, what the FDA expects in submissions, and what the current market landscape looks like.

How FDA Classifies AR/VR Medical Devices

No Dedicated AR/VR Classification Exists

The FDA has not established a specific medical device classification for head-mounted displays (HMDs) or extended reality (XR) hardware as a category. Instead, AR/VR devices are classified based on their intended use and clinical application, not the underlying display technology.

A VR headset used for surgical navigation is regulated as a stereotactic navigation system. A VR headset used for pain relief is regulated as a behavioral therapy device. The display technology is a component — the regulatory classification follows the clinical function.

Key Product Codes for AR/VR Devices

Analysis of the FDA's AR/VR device list reveals that the majority of cleared devices fall under a small number of product codes:

Source: FDA AR/VR Medical Device List, updated December 2025; Exponent analysis.

Classification Panels

The FDA's AR/VR device list shows devices reviewed across multiple panels:

Source: FDA Law Blog analysis of FDA AR/VR list, July 2025 update.

Regulatory Pathways for AR/VR Medical Devices

510(k) — The Dominant Pathway

The vast majority of AR/VR medical devices have entered the US market through the 510(k) pathway. This is because most AR/VR devices position themselves as extensions of existing, legally marketed technologies — stereotactic navigation systems, radiological visualization tools, or behavioral therapy devices — rather than entirely novel device categories.

To succeed with a 510(k) for an AR/VR device, manufacturers must demonstrate substantial equivalence to a predicate device. The key challenge is articulating how the AR/VR technology achieves the same clinical function as the predicate, even though the user interface and interaction paradigm may be fundamentally different.

Critical success factors for 510(k) AR/VR submissions:

• Identify a clear predicate with the same intended use
• Demonstrate that AR overlay accuracy meets or exceeds the predicate's performance
• Provide validation data showing the AR/VR system does not introduce new safety risks
• Address human factors comprehensively — the FDA is particularly attentive to cognitive workload, display latency, and surgeon attention diversion

De Novo — For Novel Device Types

Two AR/VR devices have been authorized through the De Novo pathway, which is appropriate for low-to-moderate risk devices that do not have a valid predicate. The De Novo pathway establishes a new classification regulation and product code, which then becomes a predicate for future 510(k) submissions.

AppliedVR's RelieVRx received De Novo authorization, establishing the QRA product code (virtual reality behavioral therapy device for pain relief, 21 CFR 890.5800). This classification now serves as a predicate for subsequent VR pain management devices.

When to consider De Novo:

• Your AR/VR device has a novel intended use not covered by existing product codes
• The device is Class I or Class II risk level
• You want to establish a new classification that creates a pathway for your product line and competitors

General Wellness Exclusion

Not all AR/VR health products are medical devices. The FDA's updated January 2026 General Wellness guidance clarifies that certain sensor-based and XR products fall outside device regulation if they:

• Are intended solely for general wellness uses (fitness tracking, relaxation, meditation)
• Are non-invasive and not implanted
• Do not make clinical claims (diagnosis, treatment, cure, prevention)
• Do not mimic clinical-grade measurements
• Do not prompt specific clinical actions

Consumer VR fitness apps, meditation experiences, and general wellness wearables with XR features typically fall under this exclusion. The distinction between general wellness and medical device hinges entirely on intended use as expressed in labeling and marketing materials.

Clinical Decision Support Exclusion

The FDA's updated January 2026 Clinical Decision Support (CDS) guidance may apply to certain AR/VR systems that display clinical information without directing specific clinical decisions. If an AR overlay simply presents imaging data without recommending a diagnosis or treatment, it may qualify for the CDS exclusion. However, most surgical navigation AR systems do not qualify because they directly guide clinical interventions.

Notable FDA-Cleared AR/VR Medical Devices

Surgical Navigation and Visualization

Therapeutic VR

Consumer-Adjacent

Unique Regulatory Challenges for AR/VR Devices

1. Display Accuracy and Registration Error

For surgical navigation AR devices, the accuracy of the anatomical overlay is a critical safety concern. If the AR overlay is misaligned with the patient's actual anatomy by even a few millimeters, the surgeon may place instruments or implants in the wrong location. FDA reviewers evaluate:

• Registration accuracy — How precisely the AR overlay aligns with the patient's anatomy
• Tracking latency — Time delay between head movement and display update (typically must be <20ms to prevent simulator sickness and maintain accuracy)
• Drift over time — Whether the overlay shifts during a long procedure
• Edge cases — Performance when the surgeon moves rapidly, looks away and back, or the tracking markers are partially occluded

2. Cognitive Workload and Attention Diversion

The FDA's Medical Extended Reality (MXR) Program conducts regulatory science research specifically on cognitive risks. When a surgeon is wearing an AR headset, their attention is split between the real surgical field and the digital overlay. If the AR interface is poorly designed, it can:

• Distract from critical intraoperative events
• Create visual clutter that obscures real anatomy
• Present too much information simultaneously, causing decision paralysis

Human factors testing for AR/VR surgical devices must specifically evaluate attention allocation and cognitive workload, not just usability.

3. Biocompatibility and Physical Safety

Head-mounted displays contact the surgeon's or patient's skin, brow, and scalp for extended periods. FDA submissions must address:

• Material biocompatibility (ISO 10993) for all patient-contacting and user-contacting components
• Electrical safety (IEC 60601-1) for powered headsets
• Electromagnetic compatibility (IEC 60601-1-2) for wireless headsets
• Optical radiation safety for display emissions
• Physical ergonomics — weight, balance, thermal output, and fatigue during extended use

4. Cybersecurity for Connected AR/VR Systems

Many AR/VR devices connect to hospital networks, cloud-based image processing servers, or robotic systems. The FDA's February 2026 cybersecurity guidance (superseding the June 2025 version) applies to these connected devices, requiring:

• Software Bill of Materials (SBOM) per Section 524B of the FD&C Act
• Cybersecurity risk assessment integrated into ISO 13485 design controls
• Secure update mechanisms for AR/VR software
• Authentication and encryption for data transmitted between headset and server

5. Headset Manufacturer Cooperation

A practical challenge identified by the ITIF (Information Technology and Innovation Foundation, June 2025 report): headset manufacturers like Meta, Apple, and HTC have not typically submitted their HMDs to the FDA as medical devices. Medical device companies that integrate HMDs into their systems often struggle to access proprietary information vital for FDA submissions, such as material composition for biocompatibility assessments and detailed specifications for image quality that meets medical standards.

EU MDR Considerations for AR/VR Devices

In the European Union, AR/VR medical devices are regulated under the EU MDR (Regulation 2017/745). Classification follows the same principles as other devices — based on intended use and risk level.

• Most surgical navigation AR devices are Class IIb under Rule 10 (active therapeutic devices) or Rule 11 (software for diagnosis/therapy)
• Therapeutic VR devices for pain relief are typically Class IIa under Rule 11
• AR visualization tools for surgical planning may be Class IIa or Class IIb depending on whether they directly guide treatment decisions

EU-specific requirements include conformity assessment by a notified body, CE marking, and compliance with the EU Cyber Resilience Act for connected devices.

The FDA's Medical Extended Reality (MXR) Program

The FDA's Digital Health Center of Excellence operates a Medical Extended Reality (MXR) Program that conducts regulatory science research on XR-based medical devices. The program focuses on:

• Developing standardized evaluation methods for AR/VR device performance
• Assessing human factors risks specific to immersive technologies
• Studying long-term effects of extended VR exposure
• Characterizing optical performance of AR displays in clinical environments
• Evaluating the effectiveness of therapeutic VR interventions

This research informs FDA's review practices and helps establish expectations for future submissions. Manufacturers should monitor the program's publications for emerging best practices.

Submission Strategy: Preparing an AR/VR Medical Device Submission

Key Sections for 510(k) Submissions

Common Deficiency Areas

Based on publicly available 510(k) decision summaries and FDA guidance, AR/VR submissions commonly receive Additional Information requests in:

• Insufficient accuracy validation — Testing under ideal laboratory conditions but not representative surgical environments
• Inadequate human factors data — Failing to evaluate cognitive workload and attention distraction risks
• Incomplete cybersecurity documentation — Not addressing Section 524B requirements for connected headsets
• Predicate selection challenges — Choosing predicates that do not adequately support the AR-specific intended use

Market Outlook

The healthcare extended reality market is projected to grow significantly through the decade. Key growth drivers include:

• Surgical navigation — AR headsets for spine, cranial, and orthopedic surgery are gaining rapid adoption as evidence accumulates. Augmedics reports over 12,000 patients treated and 65,000 pedicle screws placed using xvision (Augmedics, 2025).
• Therapeutic VR — FDA-cleared VR treatments for chronic pain, PTSD, and rehabilitation are expanding from clinical trials to prescription at-home therapy.
• Medical training — VR surgical simulation with haptic feedback allows residents to practice procedures on patient-specific digital twins before operating.
• Apple Vision Pro and consumer platforms — Apple's 510(k) clearance of DPCF for the Vision Pro signals a pathway for consumer hardware platforms to gain medical device clearances for specific clinical features.

The regulatory trajectory is clear: AR/VR devices are being treated as medical devices subject to the same rigor as traditional devices, with additional scrutiny on display accuracy, cognitive safety, and cybersecurity. Manufacturers that invest early in human factors testing, accuracy validation, and regulatory strategy will be best positioned in this rapidly growing market.

Frequently Asked Questions

Are consumer AR/VR headsets (Meta Quest, Apple Vision Pro) medical devices?

Not by default. Consumer headsets are general-purpose computing platforms. They become medical devices only when a manufacturer makes medical claims or markets a specific clinical application. Apple obtained 510(k) clearance for the Digital Prism Correction Feature — a specific Vision Pro feature — not for the headset itself. Meta Quest headsets used in clinical settings are not FDA-regulated unless a medical device company integrates them into a regulated system (as AppliedVR did with RelieVRx using the Pico G3 platform).

What product code should I use for my AR surgical navigation device?

Most AR surgical navigation devices have been classified under SBF (stereotactic navigation system, 21 CFR 882.4865). The specific product code depends on the intended use and clinical application. Review the FDA's AR/VR device list to identify devices with similar functionality and their assigned product codes.

Do I need clinical data for an AR/VR 510(k)?

It depends on the device. If you can demonstrate substantial equivalence to a predicate through bench testing, software verification, and human factors evaluation, clinical data may not be required. However, if your device has novel features, new intended uses, or significantly different technology from the predicate, the FDA may request clinical evidence. Most AR surgical navigation devices have been cleared without clinical trials, relying on accuracy testing and cadaveric studies.

How does the FDA evaluate display accuracy for AR devices?

The FDA expects manufacturers to characterize registration accuracy (the alignment between the AR overlay and the actual anatomy) under conditions representative of clinical use. This includes static accuracy measurements, dynamic tracking performance (with head movement), drift over time, and performance across the full field of view. Accuracy should be reported in millimeters with statistical confidence intervals.

Can AR/VR medical devices be used outside the operating room?

Yes. The FDA has cleared AR/VR devices for use in radiology suites (3D visualization of medical images), ophthalmology clinics (vision therapy), pain clinics (VR behavioral therapy), and even at home (prescription VR therapy like RelieVRx). The intended use and clinical setting are defined by the manufacturer and reviewed during the submission process.